Cancer Patents (Class 514/19.3)
-
Patent number: 12121565Abstract: The present disclosure provides, in part, compositions and methods of increasing the efficacy of anti-PD-1/PD-L1 antibody immunotherapy in a subject. The compositions and methods comprise an NLRP3 inhibitor used in combination with a PD-1 or PD-L1 inhibitor for the treatment of cancer.Type: GrantFiled: September 14, 2020Date of Patent: October 22, 2024Assignee: Duke UniversityInventors: Brent Hanks, Balamayooran Theivanthiran
-
Patent number: 12102670Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: January 14, 2022Date of Patent: October 1, 2024Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Phillip Mueller, Julia Leibold, Valentina Goldfinger
-
Patent number: 12065477Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: September 2, 2021Date of Patent: August 20, 2024Assignee: Immatics Biotechnologies GmbHInventors: Heiko Schuster, Janet Peper, Kevin Roehle, Philipp Wagner, Hans-Georg Rammensee
-
Patent number: 12053504Abstract: The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an ?5?1 antagonist with an ?2?1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12).Type: GrantFiled: March 25, 2022Date of Patent: August 6, 2024Assignee: CALIFORNIA NORTHSTATE COLLEGE OF PHARMACY, LLCInventor: Xiaodong Feng
-
Patent number: 12016935Abstract: Among the various aspects of the present disclosure is the provision of compositions of imaging agents and methods for use in detecting, monitoring, and evaluating CCR2 associated diseases, disorders, and conditions.Type: GrantFiled: August 25, 2020Date of Patent: June 25, 2024Assignee: Washington UniversityInventors: Yongjian Liu, Robert Gropler, Steven Brody, Daniel Kreisel
-
Patent number: 12012462Abstract: Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.Type: GrantFiled: April 10, 2019Date of Patent: June 18, 2024Assignee: Amgen Inc.Inventors: Michael John Giffin, Melissa Thomas, Christopher Murawsky, Ryan B. Case, Lawren Wu, Jed J. Wiltzius, Ruben Alvarez Rodriguez, Jun Feng
-
Patent number: 11998609Abstract: Disclosed are therapeutic self-assembling molecules including a peptide sequence conjugated to one or more antiviral therapeutics to form a peptide-based antiviral prodrug capable of self-assembly into supramolecular structures with varying morphology in aqueous solutions, which can be injected subcutaneously or intramuscularly for the long-acting treatment of chronic viral infections.Type: GrantFiled: November 7, 2022Date of Patent: June 4, 2024Assignee: The Johns Hopkins UniversityInventors: Honggang Cui, Charles Williams Flexner, Maya Monroe, Han Wang
-
Patent number: 11981731Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).Type: GrantFiled: January 15, 2020Date of Patent: May 14, 2024Assignees: The Trustees of the University of Pennsylvania, Novartis AGInventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
-
Patent number: 11965041Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.Type: GrantFiled: September 17, 2018Date of Patent: April 23, 2024Assignee: TECHNISCHE UNIVERSITAET MUENCHENInventors: Horst Otto Kessler, Chaim Gilon, Amnon Hoffman, Michael Weinmuller, Florian Rechenmacher, Joseph Fanous, Adi Klinger
-
Patent number: 11918607Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: July 16, 2021Date of Patent: March 5, 2024Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
-
Patent number: 11897925Abstract: Disclosed are compounds, compositions, uses and methods using inhibitors of the CIP2A-TOPBP1 complex or agents that inhibit phosphopeptide recognition of TOPBP1 BRCT7/8, for treatment of a cancer associated with or characterized by a homologous recombination (HR) deficiency or treatment of cancer cells having HR deficiency.Type: GrantFiled: November 6, 2021Date of Patent: February 13, 2024Assignee: Sinai Health SystemInventors: Daniel Durocher, Salomé Adam, Silvia Emma Rossi, Yibo Xue
-
Patent number: 11885796Abstract: An in vitro method for identifying an anti-cancer agent, the therapeutic efficacy of which is enhanced upon administration with a second agent that increases the expression of OPRK1 and/or BAD, comprising the steps of: a. co-incubating a population of cells with a target anti-cancer agent and said second agent and b. measuring the cytotoxicity and/or cytostasis in the population of cells; wherein the therapeutic efficacy of the target anti-cancer agent is enhanced if the cytotoxicity and/or cytostasis of the target anti-cancer agent is increased compared to a control.Type: GrantFiled: March 28, 2018Date of Patent: January 30, 2024Assignee: LDN Pharma Ltd.Inventors: Angus Dalgleish, Wai Lui
-
Patent number: 11859088Abstract: A color material aqueous solution having excellent thermal stability under acidic conditions, a method for manufacturing such a color material aqueous solution, and a blue-colored beverage are provided. Provided are: an acidic color material aqueous solution containing phycocyanin (A), a polyvalent carboxylic acid (B) containing one or more hydroxy groups, and at least one kind of nonionic emulsifier (C) selected from the group consisting of sucrose esters and polyglycerol esters, the at least one kind of nonionic emulsifier (C) having an HLB of 15 or more; a method for manufacturing an acidic color material aqueous solution including a step of dissolution in water (D); a method for manufacturing a color material aqueous solution in which the raw materials are dissolved in water; and a blue-colored beverage.Type: GrantFiled: December 10, 2019Date of Patent: January 2, 2024Assignee: DIC CorporationInventors: Hiromasa Nakamura, Hisayoshi Arai
-
Patent number: 11845795Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.Type: GrantFiled: November 8, 2019Date of Patent: December 19, 2023Assignee: INNATE PHARMAInventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
-
Patent number: 11833194Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: May 28, 2021Date of Patent: December 5, 2023Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 11820837Abstract: The present disclosure relates to a modified peptide including (i) an amino acid sequence (X)-GRT-(Y)-TLC-(Z), or (ii) an amino acid sequence having at least 40% sequence identity to the amino acid sequence (X)-GRT-(Y)-TLC-(Z), wherein X, Y, and Z are the same as described in the specification. In this regard, methods for inhibiting the activity of at least one enzyme selected from the group consisting of AKT1 (PKB alpha), AKT2 (PKB beta), MAP3K8 (COT), MST4, AURKB (Aurora B), ROCK1, RPS6KB1 (p70S6K), CDC42 BPA (MRCKA), BRAF, RAF1 (cRAF) Y340D Y341D, SGK (SGK1), MAP4K4 (HGK), AURKA (Aurora A), AURKC (Aurora C), BRAF V599E, CHEK1 (CHK1), GSG2 (Haspin), CHEK2 (CHK2), FGR, IKBKB (IKK beta), CDK7/cyclin H/MNAT1, and CDC42 BPB (MRCKB) and Abl; and inhibiting cell proliferation are also provided, as are methods for preventing or treating cancer or a neurodegenerative disease or disorder.Type: GrantFiled: June 3, 2020Date of Patent: November 21, 2023Assignee: Advanced Technologies for Novel Therapeutics, LLCInventor: Effat S. Emamian
-
Patent number: 11780898Abstract: Diagnosis, treatment and prophylaxis of diseases and conditions associated with smooth muscle cell (SMC) dysfunction are provided through the inhibition of IL-11-mediated signalling.Type: GrantFiled: October 12, 2018Date of Patent: October 10, 2023Assignees: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer, Wei Wen Lim, Benjamin Wei Ming Ng
-
Patent number: 11781142Abstract: Aspects of the disclosure relate to methods and compositions for treating pancreatic cancer (e.g., islet cell tumors). In some aspects, adeno-associated virus (AAV) may be used to deliver an interfering RNA that targets thymidylate synthase (TS).Type: GrantFiled: November 3, 2017Date of Patent: October 10, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Maria Zajac-Kaye, Kyungah Maeng
-
Patent number: 11723947Abstract: The invention relates to a peptide comprising the amino acid sequence LTLRKEPASEIAQSILEAYSQNGWANRRSGGKRP, wherein the amino acids in said amino acid sequence are D-amino acid residues, and to methods for the use of this peptide in the treatment of age-related disorders.Type: GrantFiled: January 25, 2016Date of Patent: August 15, 2023Assignee: Erasmus University Medical Center RotterdamInventor: Peterus Leonardus Josephus de Keizer
-
Patent number: 11709165Abstract: [Object] To provide a novel examination method for a cancer treatment effect, screening method for a peptide for a cancer vaccine, and peptide and composition for inducing an immune response against cancer. [Solving Means] Provided are an examination method for a cancer treatment effect and a screening method for a peptide for a cancer vaccine each including detecting an antibody against a cancer/testis antigen or an anti-p53 antibody in a sample. It is suitable that an anti-XAGE1 antibody (IgG and/or IgA) be detected, or an anti-NY-ESO-1 antibody (IgG) be detected. Also provided are a novel peptide and novel composition for inducing immune responses against cancer.Type: GrantFiled: May 10, 2018Date of Patent: July 25, 2023Assignee: KAWASAKI GAKUEN EDUCATIONAL FOUNDATIONInventors: Mikio Oka, Eiichi Nakayama, Yoshihiro Ohue, Koji Kurose
-
Patent number: 11672847Abstract: Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to be administered, and the dosages, schedules, route of administration for the regimens.Type: GrantFiled: October 10, 2019Date of Patent: June 13, 2023Assignee: Stemline Therapeutics, Inc.Inventors: Ivan Bergstein, Christopher Brooks, Thomas P. Cirrito
-
Patent number: 11579147Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.Type: GrantFiled: September 25, 2018Date of Patent: February 14, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard, Centre Leon BernardInventors: Philippe Naquet, Franck Galland, Virginie Millet, Jean-Yves Blay, Caroline Giessner
-
Patent number: 11560422Abstract: Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.Type: GrantFiled: December 29, 2014Date of Patent: January 24, 2023Inventors: Geoffrey C. Winters, Alexander L. Mandel, Elyse Marie Josée Bourque, James R. Rich, Tom Han Hsiao Hsieh
-
Patent number: 11548935Abstract: Polypeptides derived from fibronectin are presented that are neutrophil elastase-resistant and can bind to growth factors and/or enhance growth factor activity. These polypeptides are useful for enhancing wound healing in a patient.Type: GrantFiled: October 12, 2017Date of Patent: January 10, 2023Assignee: NeoMatrix Therapeutics Inc.Inventors: Richard August Clark, Fubao Lin
-
Patent number: 11505579Abstract: The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiO2 matrix gel.Type: GrantFiled: February 26, 2021Date of Patent: November 22, 2022Assignee: ASCEND BIOPHARMACEUTICALS, INC.Inventors: Clement Leong, Geoffrey Pietersz
-
Patent number: 11497740Abstract: Disclosed are methods for the use of Jumonji C demethylase inhibitors for the radiosensitization of cancers cells and the treatment and prevention of chemotherapy resistance in cancer.Type: GrantFiled: April 28, 2017Date of Patent: November 15, 2022Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Maithili P Dalvi, Elisabeth D Martínez, John D Minna, Juan Bayo-Fina, Amit Das
-
Patent number: 11498948Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: March 4, 2022Date of Patent: November 15, 2022Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
-
Patent number: 11485765Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: December 13, 2019Date of Patent: November 1, 2022Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
-
Patent number: 11479807Abstract: The present technology relates generally to methods and compositions for targeted nucleic acid sequence enrichment, as well as uses of such enrichment for error-corrected nucleic acid sequencing applications. In some embodiments, highly accurate, error corrected and massively parallel sequencing of nucleic acid material is possible using a combination of uniquely labeled strands in a double-stranded nucleic acid complex in such a way that each strand can be informatically related to its complementary strand, but also distinguished from it following sequencing of each strand or an amplified product derived therefrom. In various embodiments, this information can be used for the purpose of error correction of the determined sequence.Type: GrantFiled: March 23, 2018Date of Patent: October 25, 2022Assignee: UNIVERSITY OF WASHINGTONInventors: Scott R. Kennedy, Jesse J. Salk, Michael Hipp, Elizabeth Schmidt, Rosa Ana Risques, Daniela Nachmanson
-
Patent number: 11466072Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: October 2, 2019Date of Patent: October 11, 2022Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
-
Patent number: 11458127Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.Type: GrantFiled: June 12, 2018Date of Patent: October 4, 2022Assignee: AGIOS PHARMACEUTICALS, INC.Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
-
Patent number: 11459394Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.Type: GrantFiled: February 22, 2018Date of Patent: October 4, 2022Assignee: MACROGENICS, INC.Inventors: Liqin Liu, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini
-
Patent number: 11446321Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.Type: GrantFiled: January 15, 2018Date of Patent: September 20, 2022Assignee: Leukos Biotech, S.L.Inventors: Ruth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
-
Patent number: 11447539Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.Type: GrantFiled: February 26, 2020Date of Patent: September 20, 2022Assignee: JANSSEN BIOTECH, INC.Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
-
Patent number: 11440958Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.Type: GrantFiled: November 22, 2017Date of Patent: September 13, 2022Assignee: NATIONAL UNIVERSITY OF SINGAPOREInventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
-
Patent number: 11433098Abstract: The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.Type: GrantFiled: July 12, 2018Date of Patent: September 6, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Michelle Monje-Deisseroth, Robbie Majzner, Crystal Mackall, Christopher Mount
-
Patent number: 11427932Abstract: This document relates to materials and methods for the production of protein. In one aspect, this document provides a nucleic acid construct including a first alcohol oxidase promoter element, wherein the first alcohol oxidase promoter element includes a mutation at one or more nucleotide positions corresponding to any of nucleotide positions 668-734 relative to SEQ ID NO: 28.Type: GrantFiled: April 17, 2020Date of Patent: August 30, 2022Assignee: Impossible Foods Inc.Inventors: Martin Andrew Hoyt, Xiao Guo, Smita Shankar
-
Patent number: 11414458Abstract: The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.Type: GrantFiled: March 2, 2020Date of Patent: August 16, 2022Assignees: Agenus Inc., The Board of Regents of the University of OklahomaInventors: Donald F. Hunt, Andrew Norris, Ann Michelle English, Jeffrey Shabanowitz, William H. Hilderbrand, Oriana E. Hawkins
-
Patent number: 11400138Abstract: A method for improving a skin condition of a subject in need thereof includes administering to the subject a composition including a bioactive compound. The bioactive compound is a peptide, and includes at least one amino acid sequence as set forth in SEQ ID NO: 1 to SEQ ID NO: 11. Each of the amino acid sequence is a peptide of fish skin.Type: GrantFiled: November 17, 2020Date of Patent: August 2, 2022Assignee: TCI CO., LTD.Inventors: Yung-Hsiang Lin, Yu-Ling Wang
-
Patent number: 11382905Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.Type: GrantFiled: July 13, 2020Date of Patent: July 12, 2022Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
-
Patent number: 11339209Abstract: The invention provides novel compositions, methods, and therapeutic uses related to fusogenic protein MINION (microprotein inducer of fusion).Type: GrantFiled: November 10, 2017Date of Patent: May 24, 2022Assignee: NOVARTIS AGInventors: Stephane Corbel, Srihari Cidambi Sampath, Srinath Cidambi Sampath, Christian Schmedt, Qiao Zhang
-
Patent number: 11338027Abstract: The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.Type: GrantFiled: November 25, 2020Date of Patent: May 24, 2022Assignee: AMAL THERAPEUTICS SAInventors: Madiha Derouazi, Elodie Belnoue
-
Patent number: 11340235Abstract: The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).Type: GrantFiled: December 9, 2019Date of Patent: May 24, 2022Assignee: GA GENERIC ASSAYS GMBHInventor: Dirk Roggenbuck
-
Patent number: 11326202Abstract: The present invention provides methods, compositions and kits for enriching and determining nucleotide sequences of a plurality of target loci from a sample comprising nucleic acids. The methods comprise one or more cycles of primer extension followed by PCR amplification of target sequences using nested target-specific primers.Type: GrantFiled: November 23, 2018Date of Patent: May 10, 2022Assignee: HELITEC LIMITEDInventor: Zongli Zheng
-
Patent number: 11285220Abstract: The present invention relates to protein drug conjugates, methods of manufacturing the same and their use in therapy. In particular, the present invention relates to protein drug conjugates comprising a globular protein, an improved linker and a drug for use in targeted drug delivery applications.Type: GrantFiled: October 27, 2015Date of Patent: March 29, 2022Assignee: Iksuda Therapeutics LimitedInventors: Anthony David Baxter, Christopher Michael Birchall, David James Mansell, Justyna Helena Mysliwy, Jenny Thirlway
-
Patent number: 11253568Abstract: Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin V to the subject.Type: GrantFiled: October 2, 2015Date of Patent: February 22, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Francis G. Blankenberg
-
Patent number: 11248252Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.Type: GrantFiled: June 18, 2018Date of Patent: February 15, 2022Inventors: Zhenglun Zhu, Hong Gao
-
Patent number: 11242375Abstract: Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.Type: GrantFiled: September 2, 2016Date of Patent: February 8, 2022Assignee: Memorial Sloan Kettering Cancer CenterInventors: Prasad S. Adusumilli, Michel Sadelain
-
Patent number: 11229711Abstract: Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.Type: GrantFiled: June 6, 2014Date of Patent: January 25, 2022Assignee: Magenta Therapeutics, Inc.Inventors: David Y. Jackson, Edward Ha
-
Patent number: 11229679Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.Type: GrantFiled: April 1, 2020Date of Patent: January 25, 2022Assignee: ANCHORED RSK3 INHIBITORS, LLCInventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer